ProShares Ultra NASDAQ Biotechnology
BIB
BIB
27 hedge funds and large institutions have $36.3M invested in ProShares Ultra NASDAQ Biotechnology in 2015 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
less first-time investments, than exits
New positions opened: | Existing positions closed:
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
63% less call options, than puts
Call options by funds: $14.2M | Put options by funds: $38.2M
Holders
27
Holding in Top 10
3
Calls
$14.2M
Puts
$38.2M
Top Buyers
| 1 | +$1.92M | |
| 2 | +$1.63M | |
| 3 | +$1.42M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$789K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$591K |
Top Sellers
| 1 | -$5.5M | |
| 2 | -$4.54M | |
| 3 | -$1.43M | |
| 4 |
Morgan Stanley
New York
|
-$1.03M |
| 5 |
SG Americas Securities
New York
|
-$650K |